Status: Recruiting
CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL
Clinical Trial for the safety and efficacy of CD19-BAFF CAR-T cells therapy for refractory/relapsed B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma.
Participants needed: 20
Trial details
Phase: Early Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Zhejiang UniversityUpdated: May 14, 2024Locations: 1
Eligibility criteria
1. Gender unlimited，18< Age; [+17]
1. History of craniocerebral trauma, conscious disturbance, epilepsy, cerebrovas... [+8]